TuHURA Biosciences

IFx-3.0 is being developed for intravenous delivery of the company’s proprietary emm55 mRNA targeting CD22, which is overexpressed on cancerous B cells.

Initial results from a first in human phase 1 study of KVA12123, an anti-VISTA antibody, alone and in combination with pembrolizumab in patients with advanced solid tumors

TuHURA Biosciences acquired a VISTA-inhibiting monoclonal antibody for its immuno-oncology pipeline and planned a Phase 2 randomized trial for the second half of 2025. The acquisition also unlocked the fourth tranche of a $12.5 million PIPE financing.

The Phase 3 trial is being conducted under a Special Protocol Assessment agreement with the FDA. Its primary endpoint is overall response rate, and its key secondary endpoint is progression-free survival.

TuHURA Biosciences stockholders approved all proposals presented at the company’s meeting with Kineta.

TuHURA Biosciences announced its addition to the Russell 3000 Index, with automatic inclusion in the Russell 2000 Index, as part of the 2025 annual reconstitution.

Michael co-founded TuHURA Biosciences, earned a Ph.D. from the University of Surrey, completed an NIH postdoctoral fellowship at the University of Tennessee, and served on faculty at Auburn University and the University of Florida.

The company is developing three technologies for novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies.

The company is developing immuno-oncology technologies to overcome resistance to cancer immunotherapy. Its IFx technology is a personalized innate immune agonist, and the company planned to initiate a Phase 3 trial for Merkel cell carcinoma in 2024.

The company is developing three technologies and therapeutics to overcome primary and acquired resistance to existing cancer immunotherapies.

The terms govern use of the TuHURA website and its services, and the page directs users to the Privacy Policy.